These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 18544957)
1. Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. Kakolyris S; Souglakos J; Polyzos A; Ardavanis A; Ziras N; Athanasiadis A; Varthalitis I; Amarantidis K; Tsousis S; Vamvakas L; Vardakis N; Georgoulias V; Oncology; 2008; 74(1-2):31-6. PubMed ID: 18544957 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer. Heras P; Kritikos K; Hatzopoulos A; Xourafas V; Kritikos N; Karagiannis S; Mitsibounas D Am J Ther; 2009; 16(4):319-22. PubMed ID: 19352139 [TBL] [Abstract][Full Text] [Related]
3. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Souglakos J; Kalykaki A; Vamvakas L; Androulakis N; Kalbakis K; Agelaki S; Vardakis N; Tzardi M; Kotsakis AP; Gioulbasanis J; Tsetis D; Sfakiotaki G; Chatzidaki D; Mavroudis D; Georgoulias V Ann Oncol; 2007 Feb; 18(2):305-10. PubMed ID: 17079693 [TBL] [Abstract][Full Text] [Related]
5. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Rosati G; Cordio S; Bordonaro R; Caputo G; Novello G; Reggiardo G; Manzione L Ann Oncol; 2010 Apr; 21(4):781-786. PubMed ID: 19713248 [TBL] [Abstract][Full Text] [Related]
6. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625 [TBL] [Abstract][Full Text] [Related]
7. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. Zhao WY; Chen DY; Qi Q Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503 [TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Santini D; Vincenzi B; La Cesa A; Caricato M; Schiavon G; Spalletta B; Di Seri M; Coppola R; Rocci L; Tonini G Oncology; 2005; 69(1):27-34. PubMed ID: 16088232 [TBL] [Abstract][Full Text] [Related]
9. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692 [TBL] [Abstract][Full Text] [Related]
10. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial. Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556 [TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. Cassinello J; Alvarez JV; López MJ; Pujol E; Colmenarejo A; Segovia F; Marcos F; Filipovich E; Arcediano A; Castro IG Clin Colorectal Cancer; 2006 Mar; 5(6):429-35. PubMed ID: 16635282 [TBL] [Abstract][Full Text] [Related]
12. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer. Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088 [TBL] [Abstract][Full Text] [Related]
13. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. Borner MM; Dietrich D; Stupp R; Morant R; Honegger H; Wernli M; Herrmann R; Pestalozzi BC; Saletti P; Hanselmann S; Müller S; Brauchli P; Castiglione-Gertsch M; Goldhirsch A; Roth AD J Clin Oncol; 2002 Apr; 20(7):1759-66. PubMed ID: 11919232 [TBL] [Abstract][Full Text] [Related]
15. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385 [TBL] [Abstract][Full Text] [Related]
16. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Pfeiffer P; Sørbye H; Ehrsson H; Fokstuen T; Mortensen JP; Baltesgard L; Tveit KM; Øgreid D; Starkhammar H; Wallin I; Qvortrup C; Glimelius B Ann Oncol; 2006 Feb; 17(2):252-8. PubMed ID: 16291583 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group. Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. Meyerhardt JA; Zhu AX; Enzinger PC; Ryan DP; Clark JW; Kulke MH; Earle CC; Vincitore M; Michelini A; Sheehan S; Fuchs CS J Clin Oncol; 2006 Apr; 24(12):1892-7. PubMed ID: 16622264 [TBL] [Abstract][Full Text] [Related]
19. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809 [TBL] [Abstract][Full Text] [Related]
20. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX. Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]